WO2008046606A2 - Composition topique pour le traitement d'eczéma - Google Patents

Composition topique pour le traitement d'eczéma Download PDF

Info

Publication number
WO2008046606A2
WO2008046606A2 PCT/EP2007/009004 EP2007009004W WO2008046606A2 WO 2008046606 A2 WO2008046606 A2 WO 2008046606A2 EP 2007009004 W EP2007009004 W EP 2007009004W WO 2008046606 A2 WO2008046606 A2 WO 2008046606A2
Authority
WO
WIPO (PCT)
Prior art keywords
salt
composition according
hyaluronic acid
composition
treatment
Prior art date
Application number
PCT/EP2007/009004
Other languages
German (de)
English (en)
Other versions
WO2008046606A3 (fr
Inventor
Michael Rochel
Uwe-Bernd Rose
Roman Christian Rochel
Original Assignee
Michael Rochel
Uwe-Bernd Rose
Roman Christian Rochel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael Rochel, Uwe-Bernd Rose, Roman Christian Rochel filed Critical Michael Rochel
Publication of WO2008046606A2 publication Critical patent/WO2008046606A2/fr
Publication of WO2008046606A3 publication Critical patent/WO2008046606A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Definitions

  • the present invention relates to a topical composition in a water-based formulation suitable for application to the skin.
  • This composition is particularly suitable for the treatment of eczema, and especially eczema, atopic dermatitis and infant eczema.
  • Atopic dermatitis, neurodermatitis, atopic dermatitis and infant eczema are at the heart of this disease.
  • Treatments to date have been multimodal, including external skin treatment, which may include sebostasis compensation, anti-porginous treatment of severe itching, anti-microbial treatment for superinfection, and anti-inflammatory treatment of chronic dermatitis (see review) by H. Ott and P. Höger, Treatment of Atopic Eczema in Children, Pediatric Practice 65, 445-458 (2004).
  • EP 0 715 852 A discloses the use of hyaluronic acid or its salt as an agent for the treatment of a skin disease selected from contact dermatitis, xerosis senilis, watosis, housekeeping eczema, keratosis, chronic eczema such as neurodermatitis, miliaria and diaper dermatitis. impact.
  • a skin disease selected from contact dermatitis, xerosis senilis, watosis, housekeeping eczema, keratosis, chronic eczema such as neurodermatitis, miliaria and diaper dermatitis. impact.
  • a skin disease selected from contact dermatitis, xerosis senilis, watosis, housekeeping eczema, keratosis, chronic eczema such as neurodermatitis, miliaria and diaper dermatitis. impact.
  • a skin disease selected from contact
  • the agent may contain hyaluronic acid and / or a salt thereof.
  • hyaluronic acid for the treatment of inflammatory diseases, in particular skin or mucous membrane diseases. Mention may also be made of additives such as e.g. 2- or 3-valent metal ions, which can cross-link and stabilize by chelation, on the other hand, can accelerate the degradation of the active hyaluronic acid.
  • additives such as e.g. 2- or 3-valent metal ions, which can cross-link and stabilize by chelation, on the other hand, can accelerate the degradation of the active hyaluronic acid.
  • US 2001/0036924 A1 discloses a chemical complex and a pharmaceutical composition containing this complex, wherein the treatment application mentioned is, inter alia, topical eczema.
  • the chemical complex contains a special pyridinecarboxy derivative and a glycosaminoglycan such as hyluronic acid.
  • Other constituents of the pharmaceutical carrier system include fats or fat-like substances and, as buffering agents, salts of sodium, potassium, aluminum, magnesium or calcium.
  • Sodium hyaluronate was also used in eye drops of BIO-Fi ® brand.
  • the invention is therefore based on the object to improve the treatment of atopic dermatitis or atopic dermatitis.
  • the object is achieved by a fat-free, topical compositions in a water-based formulation suitable for application to the skin and having hyaluronic acid and / or its salt and at least one electrolyte salt as constituents and in a composition modeled on the natural amniotic fluid. It is particularly suitable for the treatment and prevention of eczema, and especially eczema, atopic dermatitis and infant eczema.
  • hyaluronic acid / hyaluronate and electrolyte salt achieves a combination effect which is believed to provide a water-retention effect in the skin and a water-repellent effect due to the application of electrolyte salt to the skin Inside the body, especially the underlying tissue in skin layers are pulled, which together strongly counteract the dryness in atopic dermatitis.
  • any known per se hyaluronic acid and / or its salt can be used. It may be of artificial and / or natural origin, due to a desired approximation and simulation to an amniotic fluid environment, the hyaluronic acid and / or its salt is preferably of natural origin. Particular preference is given to the selection of sodium hyaluronate.
  • the molecular weight of the hyaluronic acid or the salt thereof can be chosen arbitrarily. Particularly good results were obtained with hyaluronic acid and / or its salt having an average molecular weight in the range of 2 ⁇ IU 6 to 3 ⁇ IU 6 .
  • the hyaluronic acid and / or its salt is preferably essentially protein-free and free of nucleic acids.
  • the constituents mentioned are at most in an amount of 0.2%, preferably at most 0.1% and more preferably at most 0.05 wt .-%, based on the amount of in the Containing hyaluronic acid and / or its salt contained.
  • Suitable amounts of hyaluronic acid and / or its salt can be suitably adjusted as needed, for example in an amount effective against eczema and in particular atopic dermatitis, but optionally also in a purely caring and, in particular, prophylactic use.
  • the amount may also depend on whether a still to be diluted for the final use concentrate or an already dilute aqueous solution is provided. Suitable amounts are for example in the range of 0.0001 to 50 wt .-%, preferably in the range of 0.001 to 5.0 wt .-%, more preferably in the range of 0.01 to 3.0 wt .-% and in particular in the range of 0.05 to 1.0% by weight of the total composition.
  • the amount of hyaluronic acid and / or its salt may be at least 0.001 mg / ml, preferably at least 0.1 mg / ml and especially at least 1 mg / ml.
  • electrolyte salt is meant a compound which is capable of dissociating into ions, especially when dissolved in water.
  • Suitable electrolytes are organic and in particular inorganic salts.
  • organic salts are salts of organic acids, especially of naturally occurring skin acids, such as sodium, potassium and / or ammonium salts of citrate, lactate, bicarbonate, carbonate, citrate, acetate, propionate and the like.
  • Examples of possible inorganic salts include, but are not limited to, sodium, potassium, calcium, magnesium, iron and / or ammonium salts of halide such as chloride, bromide and iodide, sulfate, sulfite, carbonate, hydrogen carbonate , Phosphate, hydrogen phosphate and / or silica.
  • the electrolyte salt preferably contains at least one from the group consisting of sodium, potassium, calcium, magnesium, manganese, chloride, phosphate, hydrogen phosphate, carbonate and hydrogen carbonate.
  • the electrolyte salt is used in a mixture of different salts. Sea salt, for example salt from the Dead Sea, is particularly preferred in this sense.
  • the amount of electrolyte salt employed in the topical composition of the present invention can be varied as needed.
  • Suitable amounts of the electrolyte salt alone or in a mixture of different salts are for example in the range of 0.1 to 50 wt .-%, and preferably in the range of 1 to 30 wt .-% of the total composition.
  • the amount can also be selected depending on the desired formulation depending on the application.
  • a concentrate formulated as a bath additive may contain higher levels of salt, for example, in the range of 10 to 50 and especially 20 to 30% by weight of the total composition, while in the case of a gel formulated for application to the skin, a lower Range of salt is selected, for example in the range of 0.1 to 10 wt .-% and in particular from 1 to 5 wt .-% of the total composition.
  • the composition is preferably and advantageously adjusted to have an overall hyperosmolarity.
  • the composition is hyperosmolar to the tissue to be applied; the osmolarity of the composition is higher than that in the tissue affected by the application, and especially greater than the osmolarity prevailing in the skin.
  • the osmolarity is significantly higher, eg more than 20% higher, more than 50% higher or even more than 100% higher.
  • the osmolarity of the Composition even more than 5 times, possibly even more than 10 times de osmolarity of the affected tissue amount. This can be achieved particularly effectively that water from lower tissue regions or lower skin layers is drawn by osmosis to or under the skin surface.
  • a liquid component of the composition of the invention consists of a water base. Preferably, no further liquid components or solvents are used in addition to water.
  • the water base is preferably pure water.
  • the composition of the invention may also be lyophilized or dry and dissolved for application in the water base.
  • chondroitin sulfate can also be included in the composition according to the invention, since this substance is also suitable for a desired amniotic fluid simulation.
  • the composition according to the invention may further be added with a preservative in a suitable amount, for example in a range from 0.0001 to 5% by weight, preferably from 0.001 to 1% by weight of the total composition become.
  • a preservative in a suitable amount, for example in a range from 0.0001 to 5% by weight, preferably from 0.001 to 1% by weight of the total composition become.
  • Conventional preservatives can be used.
  • a preferred preservative is benzalkonium chloride.
  • the composition according to the invention does not contain any of the following components: fats, oils, waxes, silicones and silicone derivatives, cortisone, hydrocortisone or other cortisone derivatives, perfumes, antibiotics, dyes, pigments, thickeners, surface-active substances, emulsifiers, emollients Substances, osmolytes, alcohols, glycols, polyols, polymers, foam stabilizers and organic solvents.
  • a particularly suitable composition for the treatment of atopic dermatitis is defined as consisting exclusively of water, hyaluronic acid and / or its salt, the at least one electrolyte salt and optionally chondroitin sulfate and a substance selected from the group of preservatives.
  • the pH of the formulation of the composition according to the invention is preferably set in a range from 6.0 to 8.0 and more preferably in a range from 6.5 to 7.5.
  • composition according to the invention can be used for cosmetic, nourishing, dermatological, therapeutic and / or prophylactic purposes.
  • the composition according to the invention as described above is particularly suitable for the treatment of eczema, especially atopic dermatitis.
  • Particularly good results have been obtained in the treatment of infant eczema in childhood patients, eg, up to the age of 16 years or less, including infants up to and including 3 years of age.
  • An artificial simulation effect is most effective in toddlers of up to 1 year, especially at the age of 3 to 12 months.
  • compositions described above are suitably adapted to the ingredients described above.
  • Particular embodiments include, but are in no way limited to, a concentrate as a bath additive for bathing, or a water-based gel for application to the skin.
  • the composition of the present invention described above is included in a metering device for metering the composition into portions suitable for the desired application.
  • the metering device suitably constitutes a container with an internal volume from which the material enclosed in the internal volume of the composition according to the invention can be at least partially removed.
  • Suitable articles are, for example, a package (one or several common or separate packages of original packaging and possible refill packs), a tube, a can or other suitable container.
  • the metering device according to the invention is preferably designed in the form of a dispenser, corresponding to known soap dispensers, for dispensing the composition in the form of a fluid. Further possible embodiments and modifications of the metering device described are readily possible. The following examples describe possible embodiments and in principle substantiate the effect of the composition according to the invention, without, however, limiting the invention to:
  • a bath additive in the form of a concentrate the following ingredients are mixed into a formulation:
  • Patient # 1 male, age at diagnosis Eczema: 7 months; affected skin: face, trunk and arms and legs.
  • Patient # 2 female, age at diagnosis Eczema: 4 months; affected skin: face, neck, trunk, arms and legs.
  • Patient # 3 male, age at diagnosis Eczema: 5 months; affected skin: face, neck, trunk, arms and legs.
  • the IGA is a six-step statistical index that serves to assess the overall severity of the inflammatory process (erythema, infiltration / papule formation).
  • the IGA score ranges from 0 to 5 as follows: S ⁇ ore definition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions topiques non grasses dans une formulation appropriée pour l'application sur la peau, à base d'eau et avec de l'acide hyaluronique et/ou son sel et au moins un sel électrolytique comme composants, et éventuellement du sulfate de chondroïtine, dans une composition ressemblant au liquide amniotique. Elle est particulièrement appropriée pour le traitement et la prévention d'eczémas et notamment des neurodermites, de l'eczéma atopique et de l'eczéma du nourrisson.
PCT/EP2007/009004 2006-10-20 2007-10-17 Composition topique pour le traitement d'eczéma WO2008046606A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006049580.2 2006-10-20
DE102006049580A DE102006049580A1 (de) 2006-10-20 2006-10-20 Topische Zusammensetzung zur Behandlung von Ekzemen

Publications (2)

Publication Number Publication Date
WO2008046606A2 true WO2008046606A2 (fr) 2008-04-24
WO2008046606A3 WO2008046606A3 (fr) 2008-06-19

Family

ID=39185708

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/009004 WO2008046606A2 (fr) 2006-10-20 2007-10-17 Composition topique pour le traitement d'eczéma

Country Status (2)

Country Link
DE (1) DE102006049580A1 (fr)
WO (1) WO2008046606A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110538091A (zh) * 2018-05-29 2019-12-06 玫琳凯有限公司 局部用组合物和方法
CN106902286B (zh) * 2017-03-07 2021-01-29 上海中医药大学附属曙光医院 一种治疗婴幼儿湿疹的中药组合物、其制备方法及应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20120554A1 (it) * 2012-06-22 2012-09-21 Martini Francesco De Composizione per l'idratazione e la depurazione della cute.
US12059430B2 (en) 2022-09-29 2024-08-13 Adora Animal Health Corporation Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0136782A2 (fr) * 1983-08-09 1985-04-10 Nestle S.A. Compositions de sulfate de chondroitine/hyaluronate de sodium
EP0715852A1 (fr) * 1994-12-05 1996-06-12 Denki Kagaku Kogyo Kabushiki Kaisha Utilisation de l'acide hyaluronique ou son sel pour le traitement des désordres de la peau
US5631242A (en) * 1993-08-04 1997-05-20 Patent Biopharmaceutics, Inc. Hyaluronic acid-urea pharmaceutical compositions utilized for treatment of diseases of cutis
US20010009908A1 (en) * 1996-04-04 2001-07-26 Diego Ponzin Corneal storage fluid comprised of hyaluronic acid
US20020132790A1 (en) * 1993-07-30 2002-09-19 Luca Benedetti Pharmaceutical compositions for topical use containing hyaluronic acid and its derivatives
US20020168412A1 (en) * 1995-09-29 2002-11-14 L.A.M. Pharmaceutical Corp. Topical drug preparations
US20030021834A1 (en) * 1996-08-07 2003-01-30 Petito George D. Method for use of hyaluronic acid in wound management
US20040136925A1 (en) * 2002-08-30 2004-07-15 Giuseppe Petrigni Pharmaceutical preparation in colloidal form, useful in the treatment of skin diseases
US20050147679A1 (en) * 1998-03-24 2005-07-07 Petito George D. Composition and method for healing tissues
WO2005110439A2 (fr) * 2004-05-07 2005-11-24 S.K. Pharmaceuticals, Inc. Préparations de hyaluronane stabilisé et méthodes correspondantes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003529590A (ja) * 2000-03-21 2003-10-07 アスション デヴェロップメント エーピーエス ピリジンカルボキシ誘導体およびｈ２ヒスタミン受容体アンタゴニストからなる化学的複合体
DE10230026A1 (de) * 2002-07-04 2004-01-22 Beiersdorf Ag Kosmetische Zubereitung zur Behandlung trockener oder empfindlicher Haut
US20060165644A1 (en) * 2002-08-14 2006-07-27 Fancl Corporation Cosmetics
DE10238161A1 (de) * 2002-08-15 2004-02-26 Köhler Pharma GmbH Mineralstoff-Ampulle für die mucosale und topische Wirkstoffapplikation
DE102004002001A1 (de) * 2004-01-14 2005-08-11 Reinmüller, Johannes, Dr.med. Mittel zur Behandlung von entzündlichen Erkrankungen
WO2007099398A2 (fr) * 2005-09-27 2007-09-07 Naturalite Benelux B.V. procédés et compositions pour le traitement de la peau
ITMI20060742A1 (it) * 2006-04-13 2007-10-14 Patrizia Pattini Composizioni antibatteriche per il trattamento di infezioni delle alte e basse via aeree

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0136782A2 (fr) * 1983-08-09 1985-04-10 Nestle S.A. Compositions de sulfate de chondroitine/hyaluronate de sodium
US20020132790A1 (en) * 1993-07-30 2002-09-19 Luca Benedetti Pharmaceutical compositions for topical use containing hyaluronic acid and its derivatives
US5631242A (en) * 1993-08-04 1997-05-20 Patent Biopharmaceutics, Inc. Hyaluronic acid-urea pharmaceutical compositions utilized for treatment of diseases of cutis
EP0715852A1 (fr) * 1994-12-05 1996-06-12 Denki Kagaku Kogyo Kabushiki Kaisha Utilisation de l'acide hyaluronique ou son sel pour le traitement des désordres de la peau
US20020168412A1 (en) * 1995-09-29 2002-11-14 L.A.M. Pharmaceutical Corp. Topical drug preparations
US20010009908A1 (en) * 1996-04-04 2001-07-26 Diego Ponzin Corneal storage fluid comprised of hyaluronic acid
US20030021834A1 (en) * 1996-08-07 2003-01-30 Petito George D. Method for use of hyaluronic acid in wound management
US20050147679A1 (en) * 1998-03-24 2005-07-07 Petito George D. Composition and method for healing tissues
US20040136925A1 (en) * 2002-08-30 2004-07-15 Giuseppe Petrigni Pharmaceutical preparation in colloidal form, useful in the treatment of skin diseases
WO2005110439A2 (fr) * 2004-05-07 2005-11-24 S.K. Pharmaceuticals, Inc. Préparations de hyaluronane stabilisé et méthodes correspondantes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106902286B (zh) * 2017-03-07 2021-01-29 上海中医药大学附属曙光医院 一种治疗婴幼儿湿疹的中药组合物、其制备方法及应用
CN110538091A (zh) * 2018-05-29 2019-12-06 玫琳凯有限公司 局部用组合物和方法

Also Published As

Publication number Publication date
DE102006049580A1 (de) 2008-04-24
WO2008046606A3 (fr) 2008-06-19

Similar Documents

Publication Publication Date Title
EP2320754B1 (fr) Microémulsion
DE60313597T2 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
DE69432208T2 (de) Präparat zur Behandlung von Akne, seborrhoischer Dermatitis und anderen Hautkrankheiten
DE602005002844T3 (de) Umkehremulsionszusammensetzung mit calcitriol und clobetasol-17-propionat und ihre kosmetische und dermatologische verwendung
DE69500315T3 (de) Kosmetische oder dermatologische Wasser-in-Öl Emulsion mit hohem Gehalt an Hydroxysäuren
US4593046A (en) Method of reducing skin irritation from benzoyl peroxide
DE3032462A1 (de) Praeparate zur anwendung an oder in geweben und/oder fluessigkeiten des menschlichen oder tierischen koerpers
WO2007036376A2 (fr) Produits pour le soin de la peau
DE2046119A1 (de) Mitte) zur Behandlung der Akne
DD206324A5 (de) Verfahren zur herstellung antiherpetisch wirksamer lippenstifte
DE60004786T2 (de) Verfahren und zusammensetzung zur behandlung von akne
WO2010000348A2 (fr) Mousse de soins cutanés
EP1569724A1 (fr) Formulations contenant de la melatonine, du ginkgo biloba et de la biotine
DE2601489C2 (fr)
DE602005003138T3 (de) Zusammensetzung in sprayform mit einer kombination aus clobetasolpropionat und calcitriol, einer alkoholphase und ölphase
DE3411225C2 (fr)
DE60133038T2 (de) Hypoallergenisches nichtreizendes hautpflegemittel
DE602004004880T2 (de) Hautpflegeprodukt mit tallöl-fettsäuren und pflanzenölen für trockene und schuppende haut und behandlung von psoriasis, dermatitis und ekzemen
DE112009005131T5 (de) Topisches Medikament zur Behandlung von Psoriasis
EP3666259A1 (fr) Compositions aqueuses capables de mousser a base de biopolymeres avec une distribution de cellulures memoire de gas flexible selon son usage
WO2008046606A2 (fr) Composition topique pour le traitement d'eczéma
EP2011504B1 (fr) Produit dermatologique destiné au traitement et/ou au soin de la peau en cas de neurodermatite
EP4444418A1 (fr) Préparation pour application topique pour améliorer l'état de la peau
DE3020616C2 (fr)
WO2005034967A1 (fr) Composition pharmaceutique ou cosmetique pour traiter la peau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07819072

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE